Special Issue

Phage Therapy and Phage-Mediated Biological Control 2021

Message from the Guest Editors

Bacteriophages or phages – the viruses of bacteria – are the most abundant and potentially most diverse organisms on Earth. The majority of these viruses are lytic, meaning that, upon producing new phages, they not only kill but also lyse their bacterial hosts. Most phages target these hosts with high precision, resulting in easily predicted pharmacodynamics. Phages, in other words, have been evolving for roughly three billion years to be extremely effective at killing bacteria but, properly chosen, have little potential to do much else, such as displaying toxicity towards bodies or environments. Given these properties, phages have at least a potential to serve as antibacterial agents both within and outside of medicine. They have in fact been used as antibacterials clinically for nearly 100 years, longer even than chemical antibiotics have been known to science. Indeed, they represent highly diverse, easily discovered, readily characterized, inexpensively produced, low-toxicity antibacterial agents. Were we to include bacteriophages among 'antibiotics' then there arguably would be no antibiotic crisis.

Guest Editors

Prof. Dr. Stephen T. Abedon

Department of Microbiology, The Ohio State University, Columbus, OH 44906, USA

Dr. Diana R. Alves

Department of Pharmacology and Biomolecular Sciences, Moulsecomb, University of Brighton, Brighton BN7 4GJ, UK

Deadline for manuscript submissions

closed (31 December 2021)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/53463

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI